Variation in almotriptan effectiveness according to different prophylactic treatments

Headache

Volumn 49, Issue 9, 2009, Pages 1277-1282

  Bermejo, Pedro Emilio ^c   Dorado, Rodolfo ^a   Gomez Arguelles, Jose Maria ^b  

^a Hospital de la Zarzuela   (Spain)

^b Sanatorio del Rosario   (Spain)

^c HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

Author keywords

Almotriptan; Flunarizine; Migraine; Propranolol; Topiramate

Indexed keywords

ALMOTRIPTAN; FLUNARIZINE; PROPRANOLOL; TOPIRAMATE;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EPISODIC MIGRAINE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; PAIN ASSESSMENT; PRIORITY JOURNAL; PROPHYLAXIS; TRANSFORMED MIGRAINE; TREATMENT DURATION; TREATMENT RESPONSE; VISUAL ANALOG SCALE;

ADOLESCENT; ADRENERGIC BETA-ANTAGONISTS; ADULT; ANTICONVULSANTS; CALCIUM CHANNEL BLOCKERS; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; FLUNARIZINE; FRUCTOSE; HUMANS; MALE; MIDDLE AGED; MIGRAINE DISORDERS; PAIN MEASUREMENT; PROPRANOLOL; SEROTONIN AGONISTS; TREATMENT OUTCOME; TRYPTAMINES; YOUNG ADULT;

EID: 70349923914     PISSN: 00178748     EISSN: 15264610     Source Type: Journal    
DOI: 10.1111/j.1526-4610.2009.01491.x     Document Type: Article

References (24)

1. Lipton RB, Stewart WF, Scher AI. Epidemiology and economic impact of migraine. Curr Med Res Opin. 2001;17:4-12.
2. Lipton RB, Stewart WF, Von KM. The burden of migraine. A review of cost to society. Pharmacoeconomics. 1994;6:215-221.
3. Diener HC, Limmroth V. Advances in pharmacological treatment of migraine. Expert Opin Investig Drugs. 2001;10:1831-1845.
4. Ferrari MD, Goadsby PJ, Roon KI, Lipton RB. Triptans (serotonin, 5-HT1B/1D agonists) in migraine: Detailed results and methods of a meta-analysis of 53 trials. Cephalalgia. 2002;22:633-658.
5. Goadsby PJ. Serotonin receptors and the acute attack of migraine. Clin Neurosci. 1998;5:18-23. (Pubitemid 28106788)
6. Tepper SJ, Rapoport AM, Sheftell FD. Mechanisms of action of the 5-HT1B/1D receptor agonists. Arch Neurol. 2002;59:1084-1088.
7. Dahlof CGH, Dodick D, Dowson AJ, Pascual J. How does almotriptan compare with other triptans? A review of data from placebo-controlled clinical trials. Headache. 2002;42:99-113. (Pubitemid 34184548)
8. Pascual J, Falk RM, Piessens F, et al. Consistent efficacy and tolerability of almotriptan in the acute treatment of multiple migraine attacks: Results of a large, randomized, double-blind, placebo-controlled study. Cephalalgia. 2000;20:588-596. (Pubitemid 32269479)
9. Dodick DW. Almotriptan increases sustained painfree outcomes in acute migraine: Results from three controlled clinical trials. Headache. 2002;42:21-27.
10. Mathew NT. Almotriptan increases pain-free status in patients with acute migraine treated in placebocontrolled clinical trials. Headache. 2002;42:32-37.
11. Chen LC, Ashcroft DM. Meta-analysis examining the efficacy and safety of almotriptan in the acute treatment of migraine. Headache. 2007;47:1169-1177. (Pubitemid 47457771)
12. Cleland PG, Barnes D, Elrington GM, Loizou LA, Rawes GD. Studies to assess if pizotifen prophylaxis improves migraine beyond the benefit offered by acute sumatriptan therapy alone. Eur Neurol. 1997;38:31-38. (Pubitemid 27283076)
13. Headache Classification Committee. The International Classification of Headache Disorders, 2nd edn. Cephalalgia. 2004;24:1-160.
14. Silberstein SD, for the US Headache Consortium. Practice parameter: Evidence-based guidelines for migraine headache (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2000;55:754-762. (Pubitemid 30727712)
15. Buchanan TM, Ramadan NM. Prophylactic pharmacotherapy for migraine headaches. Semin Neurol. 2006;26:188-198.
16. Pascual J, Polo JM, Berciano J. The dose of propranolol for migraine prophylaxis. Efficacy of low doses. Cephalalgia. 1989;9:287-291. (Pubitemid 20076153)
17. Becker WJ, Christie SN, Ledoux S, Binder C. Topiramate prophylaxis and response to triptan treatment for acute migraine. Headache. 2006;46: 1424-1430. (Pubitemid 44556433)
18. Bolay H, Reuter U, Dunn AK, Huang Z, Boas DA, Moskowitz MA. Intrinsic brain activity triggers trigeminal meningeal afferents in a migraine model. Nat Med. 2002;8:136-142. (Pubitemid 34155124)
19. Haerter K, Ayata C, Moskowitz MA. Cortical spreading depression: A model for understanding migraine biology and future drug targets. Headache Curr. 2005;2:97-103. (Pubitemid 41702567)
20. Dahlöf CGH. Infrequent or non-response to oral sumatriptan does not predict response to other triptans-review of four trials. Cephalalgia. 2005;26: 98-106.
21. Shields KG, Goadsby KG. Propranolol modulates trigeminovascular responses in thalamic ventroposteromedial nucleus: A role in migraine? Brain. 2005;128:86-97.
22. Reeves RA, From GL, Paul W, Leenen FH. Nadolol, propranolol, and thyroid hormones: Evidence for a membrane-stabilizing action of propranolol. Clin Pharmacol Ther. 1985;37:157-161. (Pubitemid 15048970)
23. Nishio H, Nagakura Y, Segawa T. Interactions of Carteolol and other beta-adrenoceptor blocking agents with serotonin receptor subtypes. Arch Int Pharmacodyn Ther. 1989;302:96-106. (Pubitemid 20210267)
24. Fontebasso M. Topiramate for migraine prophylaxis. Expert Opin Pharmacother. 2007;8:2811-2823.